BriaCell having discussions with pharma companies on combination therapies
BriaCell Therapeutics (OTCQB: BCTXF) CEO Bill Williams sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.
BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizuma. BriaCell is also developing Bria-OTS, a personalized immunotherapy to treat advanced breast cancer.
Quick facts: Briacell Therapeutics Corp